Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)

Author(s):
Yoo, A.J.; Berkhemer, O.A.; Fransen, P.S.S.; Berg, L.A. van den; Beumer, D.; Lingsma, H.F.; Schonewille, W.J.; Sprengers, M.E.S.; Berg, R. van den; Walderveen, M.A.A. van; Beenen, L.F.M.; Wermer, M.J.H.; Nijeholt, G.J.L.A.; Boiten, J.; Jenniskens, S.F.M.; Bot, J.C.J.; Boers, A.M.M.; Marquering, H.A.; Roos, Y.B.W.E.M.; Oostenbrugge, R.J. van; Dippel, D.W.J.; Lugt, A. van der; Zwam, W.H. van; Majoie, C.B.L.M.; MR CLEAN Investigators
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-06-30
Language
English
Is part of
The Lancet Neurology (2016), Vol. 15, no. 7, p. 685-694
hdl
1887/112398